• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $2,227,590 worth of ResMed Common Stock (8,009 units at $278.14) (SEC Form 4)

    9/9/25 4:10:04 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Farrell Michael J.

    (Last) (First) (Middle)
    RESMED INC.
    9001 SPECTRUM CENTER BLVD

    (Street)
    SAN DIEGO CA 92123

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RESMED INC [ RMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/08/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    ResMed Common Stock 09/08/2025 M(1) 8,009 A $101.64 475,801 D
    ResMed Common Stock 09/08/2025 S(1) 8,009 D $278.1359(2) 467,792 D
    ResMed Common Stock 2,090 I Lisette and Michael Farrell Family Trust
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    ResMed Common Stock Options $101.64 09/08/2025 M 8,009 11/11/2019(3) 11/14/2025 ResMed Common Stock 8,009 $0 16,020 D
    Explanation of Responses:
    1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
    2. This transaction was executed in multiple trades at prices ranging from $275.27 - $279.57. The price reported above reflects the weighted average sale price.
    3. Represents date options first become exercisable. Options vest 1/3 per year.
    Michael J. Farrell, Chief Executive Officer 09/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    9/2/2025Hold → Outperform
    CLSA
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    1/10/2025$252.00Neutral
    Piper Sandler
    12/13/2024$250.00Hold
    Stifel
    More analyst ratings

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

    SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights initiative dedicated to advancing the science and understanding of sleep health. Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to deliver objective, non-commercial, evidence-based insights that help inform care innovation, support policy decisions, and elevate sleep as a global health priority. The announcement comes ahead of the World Sleep Congress, taking place September 5–10 in Singapore. Sl

    9/3/25 4:15:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

    SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of factors, including an aging population and increasing body mass index (BMI). The study estimates that by 2050, OSA will affect nearly 77 million U.S. adults, representing a relative1 increase of nearly 35% from 2020 and impacting 46% of adults aged 30-69. The study is the first of its kind to estimate O

    8/27/25 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs

    SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced that its AirTouch™ N30i nasal cradle mask won two prestigious Red Dot Awards: Product Design 2025 in both the Innovative Products and Medical Design & Healthcare categories. The AirTouch N30i features Resmed's first-ever nasal cushion made from fabric fused with silicone, designed to deliver both clinical performance and a therapy experience that feels more natural and comfortable making it easier for people to start and stick with CPAP therapy. Launched in October 2024, the AirTouch N30i builds on

    8/21/25 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ResMed upgraded by CLSA

    CLSA upgraded ResMed from Hold to Outperform

    9/2/25 11:05:47 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

    7/16/25 7:50:57 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded ResMed from Sector Perform to Outperform and set a new price target of $294.00

    7/15/25 8:29:55 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $RMD
    SEC Filings

    View All

    Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $2,227,590 worth of ResMed Common Stock (8,009 units at $278.14) (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    9/9/25 4:10:04 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Director Mowad-Nassar Nicole was granted 241 units of ResMed Common Stock (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    9/4/25 12:14:01 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sandercock Brett exercised 2,000 units of ResMed Common Stock at a strike of $101.64 and sold $812,310 worth of ResMed Common Stock (3,000 units at $270.77), decreasing direct ownership by 1% to 87,745 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    9/3/25 5:39:42 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by ResMed Inc.

    8-K - RESMED INC (0000943819) (Filer)

    8/18/25 4:20:28 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by ResMed Inc.

    10-K - RESMED INC (0000943819) (Filer)

    8/7/25 8:44:48 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by ResMed Inc.

    8-K - RESMED INC (0000943819) (Filer)

    7/31/25 6:30:21 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Financials

    Live finance-specific insights

    View All

    Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025

    Year-over-year revenue grows 10%, operating profit up 19%, non-GAAP operating profit up 19%Operating cash flow of $539 millionQuarterly dividend increases 13% to $0.60 per share Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended June 30, 2025. Fourth Quarter 2025 HighlightsAll comparisons are to the prior year period Revenue increased by 10% to $1.3 billion; up 9% on a constant currency basis Gross margin improved 230 bps to 60.8%; non-GAAP gross margin improved 230 bps to 61.4

    7/31/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025

    SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:  •Location:https://investor.resmed.com •Date:Thursday, July 31, 2025 •Time:1:30 p.m. PDT / 4:30 p.m. EDT •International:London, Thursday, July 31, 2025, 9:30 p.m. BSTSydney, Friday, August 1, 2025, 6:30 a.m. AEST     Please note, Resmed

    7/1/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Acquires VirtuOx

    SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

    5/1/25 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

    2/4/25 9:15:00 AM ET
    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 5:05:17 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care